The impact of adaptive energy programs on the manifestations of chronic inflammatory disease


Rainer H. Straub, MD |
The impact of adaptive energy programs on the manifestations of chronic inflammatory disease

The PROMIS initiative uses item response theory to improve assessment of patient-reported health and wellbeing

Christian Beyer, MD, and Georg Schett, MD |
Examining emerging perspectives in osteoimmunology
David Borenstein, MD, and Nadine T. James, RN, PhD |
A look at the rheumatology practice team

David S. Pisetsky, MD, PhD |
A better understanding of targets can lead to better outcomes down the road
Staff |
Rheumatology and NPs/PAs in Local Practice Models; Family Connections

Aryeh M. Abeles, MD |
Why are so many brand-name drugs approved after generic versions become available?
Staff |
The Centers for Medicare and Medicaid Services (CMS) Electronic Health Record (EHR) Incentive Program (Meaningful Use) provides for eligible physicians who demonstrate “meaningful use” of certified EHR technology to be eligible to receive up to $44,000 in Medicare incentive payments over five years or up to $63,750 in Medicaid incentive payments over six years. But what does it really mean to achieve “meaningful use” for the EHR Incentive Program, and what will your practice need to do to meet the required objectives?

Susan L. Williams Judge, MN, ARNP |
Systemic sclerosis (SSc; scleroderma) is a disease in which inflammatory and fibrotic changes result in overproduction and accumulation of collagen and other extracellular matrix proteins, resulting in intimal vascular damage, fibrosis, and occasionally organ dysfunction affecting the gastrointestinal, lung, heart, and renal systems. There are two classifications of SSc—limited cutaneous or CREST (calcinosis, Raynaud’s, esophageal dysmotility, sclerodactyly, and telangectasias) syndrome, where skin thickening occurs mainly in the distal extremities and facial/neck areas and internal organ involvement, if present, occurs later in the disease process; and diffuse cutaneous disease where there is a more rapid progression of skin thickening from distal to proximal and organ involvement can be severe and occur early in the disease. As noted by various authors, there is no “crystal ball” into which one can look to see the outcome of the disease, and involvement varies significantly from one person to the next.

James Engelbrecht, MD |
The best thing about RheumPAC is that it’s not political.
Jeffrey Lawson, MD |
I can’t tell you how many times I have conversed with a colleague about the state of health policy and heard, “It’s broken.” I invariably have to ask, “What have you done to fix it?” Often times I get a blank stare or an excuse about how Congress doesn’t listen.
Staff |
July’s Coding Answer
Staff |
July’s Coding Challenge

Staff |
Staff member Joan “Happy” Tyree has worked in arthritis since May 1982, when she joined the staff of the ACR. She began her career with the ARHP in August 1984. During her years at the ARHP, she has worked in membership and educational programs, coordinating the development of more than 26 ARHP Annual Scientific Meeting programs.
Staff |
The International League of Associations for Rheumatology (ILAR) is issuing its fourth request for proposals for projects that advance rheumatology in developing countries.

Staff |
ZPIC Medicare Audits: What’s in Store for Physicians?
Heather Haley |
The 2010 ACR fibromyalgia criteria capture the broader clinical picture and help ensure more appropriate diagnosis and management by primary care

Neil Canavan |
Project ECHO trains general practitioners and midlevel providers in the basic arts of rheumatology

Growth of ultrasound for rheumatic diseases leads many to wonder how it might fit into their practice
Catherine Kolonko |
Epidemiology makes a career of studying arthritis health disparities for Leigh Callahan, PhD
Richard S. Panush, MD |
Panush’s perspectives on selections from the literature
Information on New Approvals and Medication Safety